Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Daiichi Sankyo's Tribenzor

The US Food and Drug Administration has approved Daiichi Sankyo's Tribenzor – a combination drug for high blood pressure

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo's Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) – a combination drug for high blood pressure.

The drug is not approved for initial use, but can be administered to patients suffering from hypertension whose condition is not controlled by a combination of any two of the specified antihypertensive drug classes: angiotensin receptor blockers, calcium channel blockers and diuretics.

Tribenzor works as a combination of medications to relax blood vessels so blood can flow more freely. Olmesartan medoxomil blocks angiotensin II receptors; amlodipine blocks calcium entering into the blood vessel walls; and hydrochlorothiazide reduces water volume in the blood.

Olmesartan is sold by Daiichi under the brandnames Benicar and Olmetec; amlodipine is sold by Pfizer as Norvasc; and hydrochlorothiazide is available both as a generic and as branded products sold by a range of manufacturers.

Around 56 per cent of patients currently in treatment for the condition do not reach existing recommendations in blood pressure levels, according to Daiichi Sankyo. More than two-thirds of patients with high blood pressure will be prescribed two or more antihypertensive medications to reach these outcomes.

"Generally speaking, it can be a struggle for some patients who need to take multi-pill regimens to take their medications as prescribed," said Dr Joseph L Izzo, chief of medicine, Erie County Medical Center, Buffalo, New York.

"Tribenzor is a three-in-one pill that offers a simple, convenient and consistently effective therapy for patients, and may be just what some patients need to help bring their blood pressure to goal," he continued.

27th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics